NovoNorm (Repaglinide)
Short-Acting Insulin Secretagogue for Type 2 Diabetes
Quick Facts About NovoNorm
Key Takeaways About NovoNorm (Repaglinide)
- Meal-based dosing: Take NovoNorm immediately before or up to 30 minutes before each main meal – skip the dose if you skip a meal
- Rapid, short action: Works within 15–30 minutes with effects lasting 4–6 hours, providing targeted postprandial glucose control
- Hypoglycaemia risk: The most common side effect is low blood sugar – always carry glucose tablets and know the warning signs
- Never combine with gemfibrozil: This lipid-lowering drug can increase repaglinide levels up to 8-fold, causing dangerous hypoglycaemia
- Not for type 1 diabetes: NovoNorm only works in patients whose pancreas still produces some insulin and is exclusively for type 2 diabetes in adults
What Is NovoNorm and What Is It Used For?
NovoNorm (repaglinide) is an oral antidiabetic medication belonging to the meglitinide class. It stimulates the pancreas to release more insulin at mealtimes, thereby lowering postprandial blood glucose levels in adults with type 2 diabetes mellitus.
Type 2 diabetes is a chronic metabolic condition in which the body either does not produce enough insulin or does not respond effectively to the insulin it produces. This leads to elevated blood glucose (sugar) levels, which over time can cause serious damage to the heart, blood vessels, kidneys, eyes, and nerves. According to the World Health Organization (WHO), approximately 422 million people worldwide live with diabetes, with type 2 diabetes accounting for around 90% of all cases.
NovoNorm works through a distinct mechanism compared to many other oral antidiabetic medications. It binds to specific receptors on the beta cells of the pancreas, causing ATP-dependent potassium channels to close. This depolarises the cell membrane and triggers calcium influx, which stimulates the release of stored insulin. Importantly, this insulin-releasing effect is glucose-dependent, meaning it is most pronounced when blood glucose levels are elevated – particularly after meals.
The medication is characterised by its rapid onset of action (within 15–30 minutes) and short duration of effect (approximately 4–6 hours). This pharmacokinetic profile makes it particularly well-suited for controlling postprandial (after-meal) blood glucose spikes, a key challenge in type 2 diabetes management. Because of its short action, NovoNorm is taken before each main meal rather than at fixed times, offering considerable flexibility for patients with irregular eating patterns.
NovoNorm is used to control type 2 diabetes in adults as an adjunct to diet and exercise when these lifestyle measures alone are insufficient to achieve adequate glycaemic control. Treatment is typically initiated when diet, exercise, and weight loss have not been enough to control blood glucose levels. NovoNorm can be prescribed as monotherapy or in combination with metformin, another widely used antidiabetic agent that works through complementary mechanisms.
By maintaining better blood glucose control, NovoNorm helps prevent the long-term complications of diabetes, including cardiovascular disease, diabetic nephropathy (kidney damage), diabetic retinopathy (eye damage), and diabetic neuropathy (nerve damage). The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recognise meglitinides as a treatment option particularly for patients with significant postprandial hyperglycaemia or those who need flexible mealtime dosing.
What Should You Know Before Taking NovoNorm?
Before starting NovoNorm, inform your doctor about all medical conditions, particularly liver or kidney problems, and all other medications you take. NovoNorm must not be used in type 1 diabetes, diabetic ketoacidosis, severe liver disease, or together with gemfibrozil.
Contraindications
There are several situations in which NovoNorm must not be taken. Your doctor will assess these before prescribing the medication, but it is important that you are also aware of them:
- Allergy to repaglinide or any of the excipients in the tablets. If you have previously experienced an allergic reaction to repaglinide, you must not take NovoNorm.
- Type 1 diabetes: NovoNorm works by stimulating the pancreatic beta cells to produce insulin. In type 1 diabetes, these cells have been destroyed by an autoimmune process and cannot respond to this stimulation. Insulin therapy is the only appropriate treatment for type 1 diabetes.
- Diabetic ketoacidosis (DKA): This is a serious and potentially life-threatening complication of diabetes characterised by high blood glucose, ketone body production, and metabolic acidosis. DKA requires emergency treatment with intravenous insulin and fluids, not oral antidiabetic medications.
- Severe liver disease: Repaglinide is extensively metabolised by the liver. In patients with severe hepatic impairment, the drug cannot be adequately metabolised, leading to unpredictable accumulation and an unacceptable risk of prolonged hypoglycaemia.
- Concomitant use of gemfibrozil: Gemfibrozil, a medication used to treat high blood lipid levels (triglycerides), is a potent inhibitor of the CYP2C8 enzyme that metabolises repaglinide. Co-administration can increase repaglinide plasma concentrations by up to 8-fold, dramatically increasing the risk of severe hypoglycaemia. This combination is strictly contraindicated.
Warnings and Precautions
Discuss the following with your doctor before taking NovoNorm, as your dose may need to be adjusted or additional monitoring may be required:
- Liver problems: NovoNorm is not recommended for patients with moderate liver disease. If you have any liver condition, your doctor should perform liver function tests before and during treatment. Signs of liver problems include unexplained nausea, jaundice (yellowing of the skin or eyes), or dark urine.
- Kidney problems: Although repaglinide is primarily metabolised by the liver, patients with renal impairment may be more sensitive to its blood glucose-lowering effects. NovoNorm should be used with caution in these patients, and dose adjustments may be necessary.
- Major surgery or severe illness: During periods of physiological stress such as major surgery, serious infection, or trauma, blood glucose control can become difficult to maintain with oral antidiabetic medications. Your doctor may temporarily switch you to insulin therapy during these periods.
- Age restrictions: NovoNorm is not recommended for patients under 18 years of age or over 75 years of age, as sufficient clinical data are not available for these age groups.
Hypoglycaemia is the most important side effect of NovoNorm. Warning signs include: cold sweats, pale skin, headache, palpitations, nausea, intense hunger, temporary visual changes, drowsiness, unusual tiredness, trembling, anxiety, confusion, and difficulty concentrating. If you experience these symptoms, immediately eat glucose tablets or a sugary snack or drink and rest. If symptoms are severe or you lose consciousness, this is a medical emergency – someone should place you in the recovery position and call emergency services. Never give food or drink to an unconscious person due to the risk of choking.
Recognising High Blood Sugar (Hyperglycaemia)
Your blood sugar may become too high (hyperglycaemia) if you have taken too small a dose of NovoNorm, have an infection or fever, have eaten more than usual, or have exercised less than usual. Warning signs develop gradually and include increased urination, thirst, dry skin, and dry mouth. If you notice these symptoms, contact your doctor – your NovoNorm dose, diet, or exercise routine may need adjustment.
Pregnancy and Breastfeeding
NovoNorm should not be used during pregnancy. There are no adequate clinical studies of repaglinide in pregnant women, and animal studies have shown evidence of reproductive toxicity. If you are pregnant, planning to become pregnant, or discover that you are pregnant while taking NovoNorm, contact your doctor immediately. Your doctor will likely switch you to insulin, which is the recommended treatment for diabetes during pregnancy as it does not cross the placenta and has the most established safety profile.
NovoNorm should not be used while breastfeeding. It is not known whether repaglinide passes into breast milk, and a risk to the nursing infant cannot be excluded. If you are breastfeeding, your doctor will advise you on alternative diabetes management options.
Driving and Operating Machinery
Your ability to drive a car or operate machinery may be impaired if your blood sugar is too low or too high. Be aware that you could put yourself and others at risk. Consult your doctor about whether it is safe for you to drive, especially if you experience frequent episodes of hypoglycaemia or have reduced awareness of hypoglycaemia warning signs.
How Does NovoNorm Interact with Other Drugs?
NovoNorm interacts with many medications that can either increase or decrease its blood glucose-lowering effect. The most critical interaction is with gemfibrozil, which is strictly contraindicated. Always inform your doctor and pharmacist about all medications you are taking.
Drug interactions with repaglinide are clinically significant because they can lead to either dangerous hypoglycaemia (if the effect of repaglinide is enhanced) or inadequate blood glucose control (if the effect is reduced). Repaglinide is metabolised primarily by CYP2C8 and CYP3A4 enzymes in the liver, and drugs that inhibit or induce these enzymes can substantially alter repaglinide blood levels.
NovoNorm can be taken together with metformin if your doctor has prescribed this combination. Metformin works by reducing hepatic glucose production and improving insulin sensitivity, providing complementary blood glucose-lowering effects. However, the combination increases the risk of hypoglycaemia compared to either drug alone, and your doctor will monitor you accordingly.
Major Interactions (Avoid or Use with Extreme Caution)
| Drug | Category | Effect | Clinical Significance |
|---|---|---|---|
| Gemfibrozil | Lipid-lowering | Increases repaglinide levels up to 8-fold | CONTRAINDICATED – severe hypoglycaemia risk |
| Clopidogrel | Antiplatelet | Inhibits CYP2C8, increasing repaglinide exposure | Dose adjustment and close monitoring required |
| Cyclosporine | Immunosuppressant | Increases repaglinide plasma concentration | Close blood glucose monitoring essential |
| Clarithromycin | Antibiotic | Inhibits CYP3A4, slowing repaglinide metabolism | Increased hypoglycaemia risk during treatment |
| Itraconazole / Ketoconazole | Antifungal | CYP3A4 inhibition raises repaglinide levels | Close monitoring, possible dose reduction |
| Deferasirox | Iron chelator | CYP2C8 inhibition increases repaglinide exposure | Close blood glucose monitoring required |
| Trimethoprim | Antibiotic | CYP2C8 inhibition may increase repaglinide levels | Monitor blood glucose during antibiotic course |
Other Important Interactions
The following medications can affect how NovoNorm works. Your doctor should be informed if you are taking any of these:
Drugs that may enhance the blood glucose-lowering effect (increased hypoglycaemia risk):
- MAO inhibitors – used to treat depression
- Beta-blockers – used for high blood pressure and heart conditions. Note that beta-blockers may also mask the warning symptoms of hypoglycaemia
- ACE inhibitors – used for heart conditions and high blood pressure
- Salicylates (e.g. aspirin) – found in some pain relievers
- NSAIDs – non-steroidal anti-inflammatory drugs used for pain relief
- Octreotide – used in the treatment of certain cancers
- Alcohol – can alter the blood glucose-lowering ability of NovoNorm. Watch for signs of hypoglycaemia
Drugs that may reduce the blood glucose-lowering effect (risk of inadequate glucose control):
- Oral contraceptives (birth control pills)
- Thiazide diuretics – used to treat fluid retention and high blood pressure
- Corticosteroids – used to treat inflammatory conditions
- Danazol – used for endometriosis and breast cysts
- Thyroid hormones – used to treat hypothyroidism
- Sympathomimetics – used for asthma treatment
- Rifampicin – a powerful CYP2C8 and CYP3A4 inducer that can dramatically reduce repaglinide levels
- Phenytoin, carbamazepine, phenobarbital – antiepileptic drugs that induce hepatic enzymes
- St. John’s Wort (herbal remedy) – induces CYP3A4, potentially reducing repaglinide efficacy
What Is the Correct Dosage of NovoNorm?
The usual starting dose is 0.5 mg before each main meal. Your doctor may gradually increase the dose up to a maximum of 4 mg per meal (16 mg per day). Always take NovoNorm immediately before or up to 30 minutes before eating.
NovoNorm should always be taken exactly as prescribed by your doctor. The dose is individualised based on your blood glucose levels, and your doctor will adjust it according to your response. Do not change your dose without medical advice.
Adults
Standard Dosing
- Starting dose: 0.5 mg before each main meal
- Dose adjustments: Your doctor may increase the dose at intervals of 1–2 weeks based on blood glucose monitoring
- Maximum single dose: 4 mg before any single meal
- Maximum daily dose: 16 mg per day
- Timing: Take immediately before or up to 30 minutes before each main meal
- Administration: Swallow the tablet(s) with a glass of water
The meal-based dosing regimen is a distinctive feature of NovoNorm. Unlike many other diabetes medications that are taken at fixed times regardless of meals, NovoNorm should only be taken when you eat a main meal. If you skip a meal, you should also skip the corresponding dose of NovoNorm. Conversely, if you eat an extra main meal, you should take your NovoNorm dose before that additional meal. This flexible approach allows the medication to match your actual eating pattern, reducing the risk of hypoglycaemia between meals.
Children and Adolescents
Paediatric Use
NovoNorm is not recommended for children and adolescents under 18 years of age. There are insufficient clinical data on the safety and efficacy of repaglinide in this age group. Type 2 diabetes in children and adolescents should be managed according to paediatric endocrinology guidelines.
Elderly Patients
Use in Patients Over 75 Years
NovoNorm is not recommended for patients over 75 years of age due to insufficient clinical data. Elderly patients who are currently taking NovoNorm and are under 75 should be monitored carefully, as they may be more susceptible to hypoglycaemia due to reduced renal function, polypharmacy, and irregular eating habits.
Missed Dose
If you miss a dose because you skipped a meal, simply take your next dose as usual before your next main meal. Do not take a double dose to make up for a missed one. Since NovoNorm is taken before meals, a missed meal naturally means a missed dose – this is by design and does not require any compensatory action.
Overdose
If you take too many NovoNorm tablets, your blood sugar may drop dangerously low (severe hypoglycaemia). Symptoms include confusion, sweating, trembling, and in severe cases loss of consciousness or seizures. If you are conscious, immediately eat glucose tablets or a sugary food and drink a sweetened beverage. If a person becomes unconscious, place them in the recovery position and call emergency services immediately. Do not attempt to give food or drink to an unconscious person. Always bring your medicine packaging to the hospital so medical staff can identify what was taken.
What Are the Side Effects of NovoNorm?
The most common side effect of NovoNorm is hypoglycaemia (low blood sugar), which occurs in up to 1 in 10 patients. Other common side effects include abdominal pain and diarrhoea. Serious allergic reactions are very rare but require immediate medical attention.
Like all medicines, NovoNorm can cause side effects, although not everybody gets them. The side effects are grouped below by how frequently they occur. If you experience any side effects, particularly if they are severe or persistent, consult your doctor or pharmacist.
Common
May affect up to 1 in 10 patients
- Hypoglycaemia (low blood sugar) – the most frequent side effect. Reactions are generally mild to moderate but can occasionally progress to hypoglycaemic unconsciousness or coma. Seek immediate medical help if this occurs
- Abdominal pain (stomach pain)
- Diarrhoea
Rare
May affect up to 1 in 1,000 patients
- Acute coronary syndrome (may not be related to the medication)
Very Rare
May affect up to 1 in 10,000 patients
- Vomiting
- Constipation
- Visual disturbances
- Severe liver problems, abnormal liver function including elevated liver enzymes
- Anaphylactic reactions (severe allergic reactions with swelling, difficulty breathing, rapid heartbeat, dizziness, and sweating) – seek immediate medical attention
Unknown Frequency
Cannot be estimated from available data
- Hypersensitivity reactions (rash, itchy skin, skin redness, skin swelling)
- Nausea
It is important to distinguish between the side effects of the medication itself and the symptoms of poorly controlled diabetes. If you experience persistent gastrointestinal symptoms, visual changes, or unexplained fatigue, consult your doctor to determine whether these are related to NovoNorm, your diabetes, or another condition.
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store NovoNorm?
Store NovoNorm in its original packaging in a dry place at room temperature. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of NovoNorm ensures that the medication retains its full effectiveness throughout its shelf life. Follow these storage guidelines carefully:
- Keep out of reach and sight of children – accidental ingestion of antidiabetic medication by children can cause severe and potentially fatal hypoglycaemia
- Store in the original blister packaging – the blister pack protects the tablets from moisture, which can degrade the medication
- Check the expiry date – do not use NovoNorm after the expiry date (EXP) printed on the carton and blister foil. The expiry date refers to the last day of that month
- Protect from moisture – repaglinide tablets are moisture-sensitive. Do not transfer them to a pill organiser for extended periods
- Disposal – do not dispose of medicines via household waste or wastewater. Return unused or expired medication to your pharmacy for safe disposal. This helps protect the environment
What Does NovoNorm Contain?
The active substance in NovoNorm is repaglinide. The tablets also contain several inactive excipients that help form the tablet and ensure proper drug release.
Active Ingredient
Repaglinide is the active pharmaceutical ingredient in NovoNorm. Each tablet contains either 0.5 mg, 1 mg, or 2 mg of repaglinide, depending on the strength prescribed.
Inactive Ingredients (Excipients)
The tablets contain the following inactive ingredients: microcrystalline cellulose (E460), anhydrous calcium hydrogen phosphate, maize starch, potassium polacrilin, povidone (polyvidone), glycerol 85%, magnesium stearate, meglumine, and poloxamer. The 1 mg tablets also contain yellow iron oxide (E172) as a colourant, while the 2 mg tablets contain red iron oxide (E172).
Tablet Identification
| Strength | Colour | Shape | Marking |
|---|---|---|---|
| 0.5 mg | White | Round, convex | Novo Nordisk logo (Apis bull) |
| 1 mg | Yellow | Round, convex | Novo Nordisk logo (Apis bull) |
| 2 mg | Peach | Round, convex | Novo Nordisk logo (Apis bull) |
NovoNorm tablets are available in blister packs containing 30, 90, 120, or 270 tablets. Not all pack sizes may be marketed in your country.
Frequently Asked Questions About NovoNorm
NovoNorm (repaglinide) is used to treat type 2 diabetes mellitus in adults. It helps the pancreas produce more insulin at mealtimes, thereby lowering postprandial (after-meal) blood glucose levels. It is used as an adjunct to diet and exercise and can be prescribed alone or in combination with metformin when lifestyle measures alone do not provide adequate blood glucose control.
NovoNorm should be taken orally immediately before or up to 30 minutes before each main meal. The usual starting dose is 0.5 mg before each meal. Swallow the tablets with a glass of water. If you skip a meal, do not take the dose. Your doctor may adjust your dose up to a maximum of 4 mg per meal (16 mg per day) based on your blood glucose response.
The most common side effect is hypoglycaemia (low blood sugar), which can occur in up to 1 in 10 patients. Symptoms include cold sweats, pale skin, headache, palpitations, nausea, intense hunger, and temporary visual changes. Other common side effects include abdominal pain and diarrhoea. Severe allergic reactions are very rare but require immediate medical attention.
Yes, NovoNorm can be prescribed together with metformin if either medication alone, combined with diet and exercise, does not provide adequate blood glucose control. The two drugs work through complementary mechanisms: NovoNorm stimulates insulin release, while metformin reduces liver glucose production and improves insulin sensitivity. Your doctor will determine the appropriate dosage of each medication and monitor you for hypoglycaemia.
Gemfibrozil (a lipid-lowering medication) is a potent inhibitor of CYP2C8, the enzyme primarily responsible for metabolising repaglinide. Taking both drugs together can increase repaglinide blood levels by up to 8-fold, dramatically increasing the risk of severe, prolonged, and potentially dangerous hypoglycaemia. This combination is strictly contraindicated – your doctor will prescribe an alternative lipid-lowering medication if needed.
NovoNorm should not be used during pregnancy or breastfeeding. There are no adequate studies in pregnant women, and animal studies have shown reproductive toxicity. If you are pregnant or planning pregnancy, consult your doctor who will likely switch you to insulin therapy, which has the most established safety profile during pregnancy and does not cross the placenta.
If you stop taking NovoNorm without medical guidance, your diabetes control may worsen and blood glucose levels may rise. High blood sugar over time increases the risk of serious complications including cardiovascular disease, kidney damage, nerve damage, and eye problems. Never stop or change your diabetes treatment without first consulting your doctor, even if you feel well.
References and Sources
- European Medicines Agency (EMA). NovoNorm – Summary of Product Characteristics. Available at: ema.europa.eu/novonorm.
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786.
- World Health Organization (WHO). Global Report on Diabetes. Geneva: WHO; 2016.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. Updated 2022.
- Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacol Ther. 2003;73(6):553–563.
- Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or through a nasogastric tube. Biopharm Drug Dispos. 1998;19(5):307–314.
- British National Formulary (BNF). Repaglinide monograph. Available at: bnf.nice.org.uk.
Editorial Team
Medical Review
Content reviewed by the iMedic Medical Review Board – an independent panel of specialist physicians in endocrinology and clinical pharmacology, following international guidelines from ADA, EASD, and WHO.
Evidence Standards
All medical claims are supported by evidence level 1A (systematic reviews of randomised controlled trials) or authoritative clinical guidelines. Content follows the GRADE evidence framework.
Conflict of interest: No commercial funding. Independent medical editorial content with no pharmaceutical company sponsorship or advertising.